Novel therapies for peripheral T-cell lymphomas

Therapeutic Advances in Hematology

Volumn 4, Issue 3, 2013, Pages 173-187

  Shustov, Andrei ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

brentuximab vedotin; pralatrexate; romidepsin; T cell lymphoma; therapy

Indexed keywords

ALISERTIB; ASPARAGINASE; AURORA KINASE INHIBITOR; BELINOSTAT; BRENTUXIMAB VEDOTIN; CRIZOTINIB; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DASATINIB; DEHYDRODIDEMNIN B; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FORODESINE; HISTONE DEACETYLASE INHIBITOR; IFOSFAMIDE; LENALIDOMIDE; METHOTREXATE; MITOMYCIN; MOGAMULIZUMAB; PRALATREXATE; PREDNISONE; ROMIDEPSIN; TIPIFARNIB; VINCRISTINE; ZANOLIMUMAB;

ADD ON THERAPY; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CROSS RESISTANCE; DIARRHEA; DRUG BINDING; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG WITHDRAWAL; EDEMA; ENGRAFTMENT; ENZYME BLOOD LEVEL; FATIGUE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; ILEUS; INFECTION; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NK T CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RELAPSE; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; ST SEGMENT; STEM CELL TRANSPLANTATION; STOMATITIS; T CELL LYMPHOMA; T WAVE; THROMBOCYTOPENIA; VOMITING;

EID: 84993748576     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620713481980     Document Type: Review

References (60)

1. Anderson J. Armitage J. Weisenburger D. (1998) Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's lymphoma classification project. Ann Oncol 9: 717–720.
2. Armitage J. Vose J. Weisenburger D. (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 26: 4124–4130.
3. Coiffier B. Pro B. Prince H. Foss F. Sokol L. Greenwood M. et al. (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30: 631–636.
4. Corradini P. Tarella C. Zallio F. Dodero A. Zanni M. Valagussa P. et al. (2006) Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20: 1533–1538.
5. d'Amore F. Relander T. Lauritzsen G. Jantunen E. Hagberg H. Anderson H. et al. (2012) Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 30: 3093–3099.
6. Della Ragione F. Criniti V. Della Pietra V. Borriello A. Oliva A. Indaco S. et al. (2001) Genes modulated by histone acetylation as new effectors of butyrate activity. FEBS Lett 499: 199–204.
7. Doronina S. Toki B. Torgov M. Mendelsohn B. Cerveny C. Chace D. et al. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21: 778–784.
8. Escalon M. Liu N. Yang Y. Hess M. Walker P. Smith T. et al. (2005) Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M.D. Anderson Cancer Center experience. Cancer 103: 2091–2098.
9. Falini B. Pileri S. Pizzolo G. Durkop H. Flenghi L. Stirpe F. (1995) CD30 (ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85: 1–14.
10. Foss F. Horwitz S. Coiffier B. Bartlett N. Popplewell L. Pro B. et al. (2012) Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. Clin Lymphoma Myeloma Leuk 12: 238–243.
11. Hamblett K. Senter P. Chace D. Sun M. Lenox J. Cerveny C. et al. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10: 7063–7070.
12. Inghirami G. Pileri S. and European T-Cell Lymphoma Study Group (2011) Anaplastic large-cell lymphoma. Semin Diagnost Pathol 28: 190–201.
13. Jaccard A. Gachard N. Marin B. Rogez S. Audrain M. Suarez F. et al. (2011) Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 117: 1834–1839.
14. Krug L. Azzoli C. Kris M. Miller V. Khokhar N. Tong W. et al. (2003) 10-Propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. Clin Cancer Res 9: 2072–2078.
15. Krug L. Ng K. Kris M. Miller V. Tong W. Heelan R. et al. (2000) Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res 6: 3493–3498.
16. Kuhnel J. Chiao J. Sirotnak F. (2000) Contrasting effects of oncogene expression on two carrier-mediated systems internalizing folate compounds in fisher rat 3T3 cells. J Cell Physiol 184: 364–372.
17. Kwong Y. Kim W. Lim S. Kim S. Tang T. Tse E. et al. (2012) SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 120: 2973–2980.
18. Lee K. Yun T. Kim D. Im S. Kim T. Yoon S. et al. (2006) First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/− radiotherapy is active in stage I / II extranodal NK/T-cell lymphoma. Leuk Lymphoma 47: 1274–1282.
19. Li Y. Wang H. Jin J. Wang W. Liu Q. Song Y. et al. (2012) Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys 82: 1809–1815.
20. Li Y. Yao B. Jin J. Wang W. Liu Y. Song Y. et al. (2006) Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 24: 181–189.
21. Lopez-Guillermo A. Cid J. Salar A. Lopez A. Montalban C. Castrillo J. et al. (1998) Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. classification. Ann Oncol 9: 849–855.
22. Morabito F. Gallamini A. Stelitano C. Callea V. Guglielmi C. Neri S. et al. (2004) Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi. Cancer 101: 1601–1608.
23. Nagafuji K. Fujisaki T. Arima F. Ohshima K. (2001) L-Asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 74: 447–450.
24. Nakajima H. Kim Y. Terano H. Yoshida M. Horinouchi S. (1998) FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241: 126–133.
25. Nowak-Gottl U. Ahlke E. Fleischhack G. Schwabe D. Schobess R. Schumann C. et al. (2003) Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood 101: 2529–2533.
26. O'Connor O. Hamlin P. Portlock C. Moskowitz C. Noy A. Straus D. et al. (2007) Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 139: 425–428.
27. O'Connor O. Horwitz S. Hamlin P. Portlock C. Moskowitz C. Sarasohn D. et al. (2009) Phase II–I–II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 27: 4357–4364.
28. O'Connor O. Pro B. Pinter-Brown L. Bartlett N. Popplewell L. Coiffier B. et al. (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29: 1182–1189.
29. Oflazoglu E. Kissler K. Sievers E. Grewal I. Gerber H. (2008) Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 142: 69–73.
30. Piekarz R. Frye R. Prince H. Kirschbaum M. Zain J. Allen S. et al. (2011) Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117: 5827–5834.
31. Piekarz R. Robey R. Sandor V. Bakke S. Wilson W. Dahmoush L. et al. (2001) Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98: 2865–2868.
32. Piekarz R. Robey R. Zhan Z. Kayastha G. Sayah A. Abdeldaim A. et al. (2004) T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103: 4636–4643.
33. Pro B. Advani R. Brice P. Bartlett N. Rosenblatt J. Illidge T. et al. (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30: 2190–2196.
34. Reimer P. Rudiger T. Geissinger E. Weissinger F. Nerl C. Schmitz N. et al. (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27: 106–113.
35. Rudiger T. Weisenburger D. Anderson J. Armitage J. Diebold J. MacLennan K. et al.; Non-Hodgkin's Lymphoma Classification Project (2002) Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin's lymphoma classification project. Ann Oncol 13: 140–149.
36. Sandor V. Bakke S. Robey R. Kang M. Blagosklonny M. Bender J. et al. (2002) Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8: 718–728.
37. Savage K. Chhanabhai M. Gascoyne R. Connors J. (2004) Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 15: 1467–1475.
38. Schmid F. Sirotnak F. Otter G. de Graw J. (1985) New folate analogs of the 10-deaza-aminopterin series: Markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice. Cancer Treat Rep 69: 551–553.
39. Schmitz N. Trumper L. Ziepert M. Nickelsen M. Ho A. Metzner B. et al. (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-grade Non-Hodgkin Lymphoma Study Group. Blood 116: 3418–3425.
40. Shustov A. Gopal A. Lupinacci T. Johnson D. Zecha G. Cherian S. (2010) Successful peripheral blood hematopoietic cell mobilization and compositional autograft analysis in a patient with peripheral T-cell lymphoma treated with single agent romidepsin. Meeting Proceedings, International T-cell Lymphoma Forum 2010, Lahaina, HI, USA. Abstract TR_2.
41. Shustov A. Rosenblatt J. Kennedy D. Fanale M. (2012) Peripheral blood stem cell (PBSC) mobilization and engraftment after brentuximab vedotin treatment in anaplastic large cell lymphoma (ALCL) patients. Ann Oncol 23(Suppl. 9): ix353, abstract 1083P.
42. Simon A. Peoch M. Cassasus P. Deconick E. Colombat P. Desablens B. et al. (2010) Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T-cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haemtol 151:159–166.
43. Sirotnak F. de Graw J. Colwell W. Piper J. (1998) A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 42: 313–318.
44. Sirotnak F. de Graw J. Moccio D. Samuels L. Goutas L. (1984 a) New folate analogs of the 10-deaza-aminopterin series. basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol 12: 18–25.
45. Sirotnak F. de Graw J. Schmid F. Goutas L. Moccio D. (1984 b) New folate analogs of the 10-deaza-aminopterin series. further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models. Cancer Chemother Pharmacol 12: 26–30.
46. Sirotnak F. Schmid F. Samuels L. de Graw J. (1987) 10-Ethyl-10-deaza-aminopterin: structural design and biochemical, pharmacologic, and antitumor properties. NCI Monogr (5): 127–131.
47. Sirotnak F. Tolner B. (1999) Carrier-mediated membrane transport of folates in mammalian cells. Annu Rev Nutr 19: 91–122.
48. Ueda H. Manda T. Matsumoto S. Mukumoto S. Nishigaki F. Kawamura I. et al. (1994 a) FR901228, a novel antitumor bicyclic depsipeptide produced by chromobacterium violaceum no. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot 47: 315–323.
49. Ueda H. Nakajima H. Hori Y. Fujita T. Nishimura M. Goto T. Okuhara M. (1994 b) FR901228, a novel antitumor bicyclic depsipeptide produced by chromobacterium violaceum no. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot 47: 301–310.
50. Ueda H. Nakajima H. Hori Y. Goto T. Okuhara M. (1994) Action of FR901228, a novel antitumor bicyclic depsipeptide produced by chromobacterium violaceum no. 968, on ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem 58: 1579–1583.
51. Uno M. Tsuchiyama J. Moriwaki A. Noguchi T. Mizoguchi K. Ogino T. et al. (2001) In vitro induction of apoptosis for nasal angiocentric natural killer cell lymphoma-derived cell line, NK-YS, by etoposide and cyclosporine A. Br J Haematol 113: 1009–1014.
52. van Lint C. Emiliani S. Verdin E. (1996) The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5: 245–253.
53. Wang H. Li Y. Wang W. Jin J. Dai J. Wang S. et al. (2012) Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys 82: 1115–1121.
54. Yamaguchi M. Kita K. Miwa H. Nishii K. Oka K. Ohno T. et al. (1995) Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 76: 2351–2356.
55. Yamaguchi M. Kwong Y. Kim W. Maeda Y. Hashimoto C. Suh C. et al. (2011) Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-cell Tumor Study Group study. J Clin Oncol 29: 4410–4416.
56. Yamaguchi M. Suzuki R. Kwong Y. Kim W. Hasegawa Y. Izutsu K. et al. (2008) Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 99: 1016–1020.
57. Yamaguchi M. Tobinai K. Oguchi M. Ishizuka N. Kobayashi Y. Isobe Y. et al. (2009) Phase I / II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan clinical oncology group study JCOG0211. J Clin Oncol 27: 5594–5600.
58. Yamaguchi M. Tobinai K. Oguchi M. Ishizuka N. Kobayashi Y. Isobe Y. et al. (2012) Concurrent chemoradiotherapy for localized nasal natural Killer/T-cell lymphoma: an updated analysis of the Japan Clinical Oncology Group study JCOG0211. J Clin Oncol 30: 4044–4046.
59. Yong W. Zheng W. Zhang Y. Zhu J. Wei Y. Zhu D. et al. (2003) L-Asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 78: 163–167.
60. Younes A. Bartlett N. Leonard J. Kennedy D. Lynch C. Sievers E. et al. (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363: 1812–1821.